BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2026 7:28:51 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-08-20 04:05 |
|
Peer-Review Started |
|
2025-08-20 04:05 |
|
First Decision by Editorial Office Director |
|
2025-10-10 03:13 |
|
Return for Revision |
|
2025-10-10 03:13 |
|
Revised |
|
2025-11-23 08:34 |
|
Publication Fee Transferred |
|
2025-11-26 10:01 |
|
Second Decision by Editor |
|
2026-01-13 02:34 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-14 06:41 |
|
Articles in Press |
|
2026-01-14 06:41 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-29 09:09 |
|
Publish the Manuscript Online |
|
2026-04-08 07:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhi-Huan Lin, Yan He, Hai-Xia Xu and Liang Xiao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Shen Zhen City |
No. JCYJ20220530151002004 |
|
| Corresponding Author |
Hai-Xia Xu, MD, Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, No. 3002 Sungang West Road, Futian District, Shenzhen 518035, Guangdong Province, China. xhx198345@vip.163.com |
| Key Words |
Hepatocellular carcinoma; Cost-effectiveness; Network meta-analysis; First-line treatment; China |
| Core Tip |
The economic evaluation of various first-line treatment regimens for advanced hepatocellular carcinoma is crucial, yet such analyses remain scarce. This study conducted a network meta-analysis of 23 first-line regimens for advanced hepatocellular carcinoma and subsequently performed a cost-effectiveness analysis on seven highly efficacious regimens from the perspective of the Chinese healthcare system. The results indicated that lenvatinib combined with transarterial chemoembolization emerged as the most favorable first-line treatment under current economic conditions in China, achieving a 67.9% probability of being the most cost-effective option. This study contributes a novel perspective to inform clinical decision-making for healthcare professionals. |
| Publish Date |
2026-04-08 07:28 |
| Citation |
Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i4/113266.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i4.113266 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
